Arezoo Esmaeili | Molecular Biology | Best Researcher Award

Published on by Academic Awards

Ms. Arezoo Esmaeili | Molecular Biology | Best Researcher Award

Islamic Azad University | Iran

Ms. Arezoo Esmaeili is a senior researcher in viral immunology and cancer biology based in Mashhad, Iran, with over 13 years of experience in translational research focusing on EBV-, CMV-, and HCV-associated diseases. She holds an MSc in Biotechnology-Microbial from Islamic Azad University, Damghan Branch, and a BSc in Cellular and Molecular Biology-Microbiology. Her expertise lies in designing and evaluating peptide-based vaccines and immunotherapies targeting viral antigens in cancer, with notable publications including systematic reviews on peptide vaccines, viral reactivation post-COVID-19, and the role of Epstein–Barr virus in programmed cell death and cancer development. Ms. Arezoo Esmaeili has led cross-disciplinary R&D projects as Research and Development Manager at Mashhad Pharma Co., guided biomedical research at Zist Fan Teb Co., and managed translational research projects at Mojrian Salamat Farandishan Co. She is skilled in molecular biology techniques, vaccine design, bioinformatics, and research translation, and actively contributes as a peer reviewer for international journals, participates in global conferences, and pursues cutting-edge training in mRNA technology, immunogenomics, and cancer therapeutics.

Profile: Google Scholar

Featured Publications

  • Amel Jamehdar, S., Tabaei, S., Mashkani, B., Karimi, R., Motallebnezhad, M., & Esmaeili, A. (2019). Construction of Epstein–Barr virus cocktail peptide fused with Fcγ of IgG: As a potential delivery system for vaccine development. Bioengineered, 10(1), 689–696.

  • Jamal, M. K., Sanaei, B., Naderi, M., Past, V., Abadi, S. H. A., Khazaei, R., & Esmaeili, A. (2025). Investigating the recent outbreak of dengue fever in Iran: A systematic review. The Egyptian Journal of Internal Medicine, 37(1), 1–21.

  • Esmaeili, A., Awasthi, P., & Tabaee, S. (2025). Beyond immortality: Epstein–Barr virus and the intricate dance of programmed cell death in cancer development. Cancer Treatment and Research Communications, 43, 100880.

  • Naderi, M., Naderi, M., Keramati Jamal, M., Past, V., Esmaeili, A., Khabazian, A., Hashemi Ali Abadi, S., Saremi, G., Asghari, Sh., & Moghimi, Sh. (2025). The reactivation of various viruses following COVID-19 infection: A systematic review. Future Virology, 20(3–4), 99–111.

  • Tabaei, S., Mashkani, B., Esmaili, A., Karimi, R., & Jamehdar, S. A. (2016). Design of cocktail peptide vaccine against Cytomegalovirus infection. Iranian Journal of Basic Medical Sciences, 19(4), 449–454.

Ghazal Tansir | Oncology | Best Researcher Award

Published on by Academic Awards

Dr. Ghazal Tansir | Oncology | Best Researcher Award

All India Institute Of Medical Sciences Delhi | India

Dr. Ghazal Tansir, is an accomplished medical oncologist and researcher with a distinguished academic and clinical trajectory, holding an MBBS from Vardhman Mahavir Medical College, an MD in Internal Medicine from PGIMER, and a DM in Medical Oncology from AIIMS, New Delhi. She has served as Senior Resident and Research Consultant at AIIMS and is currently Assistant Professor at CAPFIMS-AIIMS, New Delhi. Dr. Tansir is an active member of the American Society of Clinical Oncology, European Society of Medical Oncology, and Indian Society of Medical and Pediatric Oncology. She has received multiple honors, including gold medals in Community Medicine and Ophthalmology, the AK Gadpayle Gold Medal in MD, selection for the ACORD protocol development workshop, the ASCO Merit Award, the ESMO Travel Grant, and the IDEA Award by Conquer Cancer. Her research contributions encompass over fifteen publications, focusing on rare cancers, sarcomas, and translational oncology, with studies on synovial sarcoma, mesenchymal chondrosarcoma, desmoid tumors, Li Fraumeni syndrome, and young-onset lung cancer. Dr. Ghazal Tansir has presented her work extensively at international conferences, including ASCO, ESMO, and the Connective Tissue Oncology Society, earning recognition for clinical and translational research excellence, making her a highly impactful researcher in medical oncology.

Profile: Google Scholar

Featured Publications

Tansir, G., Gupta, C., Mehta, S., Kumar, P., Soneja, M., & Biswas, A. (2017). Expanded dengue syndrome in secondary dengue infection: A case of biopsy proven rhabdomyolysis induced acute kidney injury with intracranial and intraorbital bleeds. Intractable & Rare Diseases Research, 6(4), 314–318.

Kumar, P., Tansir, G., Sasmal, G., Dixit, J., & Sahoo, R. (2016). Left pulmonary agenesis with right lung bronchiectasis in an adult. Journal of Clinical and Diagnostic Research: JCDR, 10(9), OD15.

Tansir, G., Kumar, P., Pius, A., Sunny, S. K., & Soneja, M. (2019). Pseudo-pseudo Meigs’ syndrome: A rare presentation of systemic lupus erythematosus. Reumatismo, 71(2), 108–112.

Biswas, S., Kumar, P., Tansir, G., & Biswas, A. (2019). Case report: Cardiac tamponade in dengue hemorrhagic fever: An unusual manifestation of a common disease. The American Journal of Tropical Medicine and Hygiene, 101(2), 448.

Tansir, G., Rastogi, N., Ramteke, P., Kumar, P., Soneja, M., Biswas, A., Kumar, S., & Jorwal, P. (2017). Disseminated mucormycosis: A sinister cause of neutropenic fever syndrome. Intractable & Rare Diseases Research, 6(4), 310–313.

Shixun Wang | Cardiology | Best Researcher Award

Published on by Academic Awards

Dr. Shixun Wang | Cardiology | Best Researcher Award

Professor at Weifang People’s Hospital, China

Dr. Wang Shixun 👨‍⚕️, born in October 1979, is a distinguished cardiovascular specialist at Weifang People’s Hospital. He earned his doctorate in Cardiovascular Medicine from Weifang Medical College in 2006 and has over 18 years of clinical experience. Currently serving as Deputy Director, he is applying for the position of Chief Physician 👨‍🔬. Known for his excellence in clinical practice, he received top evaluation ratings from 2018 to 2021 🌟. Dr. Wang demonstrates strong computer and foreign language skills 💻🗣️ and is highly respected for his dedication to cardiovascular care and hospital leadership ❤️🏥.

Publication Profile

Scopus

Orcid

Academic Background

Dr. Wang Shixun 👨‍⚕️ graduated from Weifang Medical College in July 2006 🎓, earning his doctorate in Cardiovascular Medicine ❤️. Immediately after graduation, he began his medical career at Weifang People’s Hospital 🏥, demonstrating a seamless transition from academic training to clinical practice. With a strong foundation in medical education and a passion for patient care 💉, Dr. Wang quickly established himself as a dedicated healthcare professional. His long-term commitment to the same institution reflects both loyalty and deep institutional knowledge 📘, making him a valuable asset to the hospital and the broader medical community 🌟.

Professional Experience

Dr. Wang Shixun 👨‍⚕️ obtained his current professional and technical qualifications in March 2017 and has since shown remarkable growth in the field of Cardiovascular Medicine ❤️. He was first appointed to his current role in September 2018 and has accumulated five years of dedicated service in this position. Dr. Wang now applies for the title of Chief Physician, reflecting his advanced clinical expertise and leadership readiness 🧠. He also serves as Deputy Director 🏥, balancing administrative responsibilities with medical duties. Additionally, he has demonstrated proficiency in computer applications 💻, enhancing his effectiveness in modern healthcare delivery.

Awards and Honors

Dr. Wang Shixun 👨‍⚕️ has consistently demonstrated excellence in his medical career, earning outstanding performance evaluations for four consecutive years—2018, 2019, 2020, and 2021 🏅. These “Excellent” ratings reflect his dedication, clinical skill, and strong work ethic in the field of Cardiovascular Medicine ❤️. In 2022, he continued to maintain a high standard with a “Qualified” rating ✅. His consistent recognition by peers and superiors underscores his commitment to medical excellence and patient care 🙌. These honors highlight Dr. Wang’s growing influence and leadership within the hospital and the broader medical community 🏥✨.

Research Focus

Dr. Wang Shixun 👨‍⚕️ is deeply engaged in the field of Cardiovascular Medicine, with a strong focus on clinical research aimed at improving patient outcomes and advancing treatment strategies for heart-related conditions ❤️🫀. His work emphasizes evidence-based practices, integrating the latest medical advancements into routine care 🧬📊. As Deputy Director at Weifang People’s Hospital 🏥, he actively participates in research initiatives and fosters a collaborative environment for innovation and knowledge sharing 🤝💡. With his solid academic foundation and practical experience, Dr. Wang continues to explore new frontiers in cardiovascular healthcare to benefit patients and the medical community 🌍📚.

Publication Top Notes

📝 A Case of Treatment With a Combination of Covered Stents and Artificial Blood Vessel for Iliac Artery Rupture During Transcatheter Aortic Valve Replacement

📅 Year: 2025 | 📚 Journal: Clinical Case Reports

Efficacy and Safety of Different Dosing Regimens of Colchicine in Patients with Coronary Artery Disease: A Network Meta-analysis of 15 Randomized Controlled Trials

Effect of levocarnitine on TIMP-1, ICAM-1 expression of rats with coronary heart disease and its myocardial protection effect

Serum Amyloid a Promotes Visfatin Expression in Macrophages

Plumbagin mediates cardioprotection against myocardial ischemia/reperfusion injury through Nrf-2 signaling

Conclusion

Dr. Wang Shixun is a highly skilled and experienced medical professional in the field of Cardiovascular Medicine, currently serving as Deputy Director at Weifang People’s Hospital and applying for the position of Chief Physician. With a doctoral degree and nearly two decades of clinical service since 2006, he has consistently demonstrated excellence, as reflected in multiple years of outstanding evaluations. He also shows proficiency in foreign languages and computer applications. However, while his clinical credentials and leadership are commendable, there is currently limited evidence of significant research contributions—such as peer-reviewed publications, funded projects, or academic impact—needed to support a strong case for a Best Researcher Award.